The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Could a new ADC project distract attention away from evorpacept?
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.